Freenome IPO
Freenome is a biotechnology company developing blood-based tests for early cancer detection using artificial intelligence and genomics. The company's platform aims to detect cancer before symptoms appear, which could significantly improve patient outcomes and represents a large market opportunity in precision medicine.
Key Facts
| Industry | Biotechnology |
| Founded | 2014 |
| Headquarters | South San Francisco, CA |
| Employees | ~400 |
| Website | freenome.com |
| Funding | Series A2 at $2.3B valuation. Total raised: ~$1.1B |
About Freenome
Freenome is a biotechnology company developing next-generation blood tests for early cancer detection using artificial intelligence and genomics. The company's multiomics platform analyzes circulating tumor DNA, proteins, and other biomarkers in blood samples to identify cancer signatures before symptoms appear. Their lead program focuses on colorectal cancer screening, aiming to provide a simple blood test alternative to traditional colonoscopies.
The company's approach combines machine learning algorithms with advanced molecular biology to detect patterns that indicate the presence of cancer. Freenome has conducted large-scale clinical studies and partnerships with healthcare systems to validate their technology. Their platform has the potential to revolutionize cancer screening by making early detection more accessible and less invasive, particularly for populations who may avoid traditional screening methods due to discomfort or accessibility issues.
IPO Status
Freenome remains a private company and has not announced any IPO plans. The company has raised substantial venture funding, including a Series C round that reportedly valued the company at over $1 billion, achieving unicorn status in the competitive cancer diagnostics space. While the company's technology and market potential could make it an attractive IPO candidate, no confirmed details about timing or plans have been disclosed. The regulatory pathway for cancer screening tests can be lengthy, and companies in this space often wait until they have significant clinical validation before going public.
Competitors
Frequently Asked Questions
Does Freenome have a stock?
No, Freenome has not had an IPO and remains privately held. The company has not announced any plans to go public.
When is the Freenome IPO date?
There is no confirmed IPO date for Freenome as the company has not announced plans to go public.
How can I buy Freenome stock?
You cannot currently buy Freenome stock as it is privately held and not available on public markets.
Stay Updated on the Freenome IPO
Get real-time alerts when Freenome files for an IPO, prices shares, or begins trading.
Get IPO Alerts